Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 15.07.2019 | 10:21

Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings

Carl Zeiss Meditec AG / Key word(s): 9 Month figures/Quarter Results
Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings

15-Jul-2019 / 10:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings

Jena, July 15, 2019

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of around EUR 1,028 million in the first nine months of fiscal year 2018/19, based on preliminary data. This corresponds to revenue growth of around 11 % vs. the previous year's value of EUR 926.3 million. After adjustment for currency effects[1], growth amounted to approximately 9 %.

Earnings before interest and taxes (EBIT) is expected to amount to around EUR 184 million after nine months (previous year: EUR 134.8 million). EBIT margin (EBIT / revenue in %) is approximately 17.9% (previous year: 14.6%). A positive development of the product mix with a higher share of consumables contributed to this increase. Earnings per share grew to around EUR 1.22 (previous year: EUR 0.92).

For fiscal year 2018/19, Carl Zeiss Meditec now expects revenue at the upper end of the previous forecast range of EUR 1,350 to EUR 1,420 million. Due to the strong current trend, EBIT margin is expected to exceed the previous forecast range of 15.0 % to 17.5 %.

From today's point of view and in light of planned strategic investments in research & development, management does not expect a further increase in EBIT margin in the coming fiscal year 2019/20. Carl Zeiss Meditec expects to provide a more precise forecast for fiscal year 2019/20 with publication of fiscal year 2018/19 results by Dec 6, 2019. The nine months quarterly statement for fiscal year 2018/19 will be published on August 9, 2019.

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116

[1] Currency-adjusted revenue growth is calculated by converting revenue of the previous year's period with current exchange rates.

15-Jul-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

Deutsche Post AG: Deutsche Post AG hebt Prognose für 2020 auf

07. April 2020, 18:21

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie


Original-Research: DATRON AG (von BankM AG): n.a.

07. April 2020